Fresh Tracks Therapeutics, Inc.

Revenue for the third quarter of 2022 was approximately $0.5 million, compared with $0.1 million in the third quarter of 2021. R&D expense was $3.6 million, down from $10.2 million year over year, and G&A expense was $3.0 million versus $3.3 million a year ago. Net loss was $6.0 million, compared with a net loss of $13.3 million in the prior-year quarter. Cash and cash equivalents were $11.3 million as of September 30, 2022, and management said cash plus up to $6 million of expected near-term Botanix payments should be sufficient to fund operations for at least the next 12 months.

Rob Brown framed the quarter as a continuation of the company’s strategic reset, emphasizing the rebranding to Fresh Tracks and the move toward a pipeline of novel autoimmune and inflammatory disease assets. He stressed that FRTX-02 is on track for early-2023 data, that FRTX-10 remains a key preclinical priority, and that the company is actively hearing interest from potential partners for both lead platforms. His tone was upbeat but measured, repeatedly tying value creation to upcoming data and continued development.

Bert Marchio highlighted a solid liquidity position, citing $11.3 million in cash and cash equivalents at quarter-end and up to $6 million of expected near-term Botanix payments as enough to fund operations for at least 12 months. He walked through the quarter’s financials: revenue of about $0.5 million, R&D of $3.6 million, G&A of $3.0 million, and a net loss of $6.0 million. He also noted the year-over-year decline in R&D was driven mainly by lower SB-related clinical costs, the Voronoi license upfront expense, and lower regulatory/compliance fees, partly offset by higher FRTX-02 clinical spending.

Analysts focused on whether the Part 2 atopic dermatitis study would enroll biologic-naive and JAK-inhibitor-naive patients, and management said patients must be off biologics such as dupilumab for 6 months before entry and will most likely be JAK-inhibitor naive, subject to an exclusion period. Questions also centered on partnering: management said it is getting regular interest in both lead programs, but there is no fixed ideal time to partner and any deal structure would depend on the drug, data, and company position. On biomarkers and the AD setting, management said the study is intentionally short and primarily meant to show target engagement and preliminary efficacy, with broader biomarker work intended to inform later development beyond atopic dermatitis.